Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Orthocell Ltd ( (AU:OCC) ) is now available.
Orthocell Limited announced it has received a $3.18 million R&D Tax Incentive refund from the Australian Government, bolstering its cash reserves to approximately $33 million. This financial boost supports Orthocell’s strategy to enter the US market with its Remplir™ product by early 2025, potentially enhancing its position in the global medical device market and providing significant growth opportunities.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company focused on developing products for the repair of bone and soft tissue injuries. The company’s product portfolio includes the CelGro™ platform of collagen medical devices, Striate+™ for dental applications, Remplir™ for peripheral nerve reconstruction, and SmrtGraft™ for tendon repair. Orthocell is advancing its tendon cell therapy in the US and has a global distribution network.
YTD Price Performance: 0.74%
Average Trading Volume: 1,538,670
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$317.9M
Learn more about OCC stock on TipRanks’ Stock Analysis page.
